S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Alpha Tau Shares Rise 13% on Glioblastoma Trial Results

All six evaluable patients in Alpha Tau Medical’s study of its Alpha DaRT therapy for recurrent glioblastoma had an objective response, the company said. Five had no measurable tumor remaining at the treated site, while the sixth had a 58% reduction in tumor measurements.

Alpha Tau Shares Rise 13% on Glioblastoma Trial Results

Alpha Tau shares rose 13% to $15.15 in premarket trading on Monday. At Friday’s close, the stock had more than doubled year to date.

The company said no unanticipated serious adverse events had occurred in the trial. One grade 3 serious adverse event, reported in May, was a seizure in a patient with a history of seizures.

Chief Executive Uzi Sofer said the results had exceeded the company’s expectations, particularly given the difficulty of treating glioblastoma. He described recurrence as “virtually inevitable.” Alpha Tau plans to keep monitoring patients as their scans mature and continue enrollment toward 20 participants. The company expects that enrollment to support an application to market Alpha DaRT for glioblastoma.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!